Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206296 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01206296: Clinical Trial Phase 2 study, sponsored by Medstar Health Research Institute.
NCT01206296 is a Phase 2 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01206296, a Phase 2 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a phase II study evaluating the use of intraperitoneal gemcitabine given intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer. The primary objective of this study is to evaluate the overall safety of intraperitoneal gemcitabine given intraoperatively and postoperatively for adjuvant treatment of resectable pancreatic adenocarcinoma. The secondary objectives are to evaluate the efficacy of this treatment regimen as reflected in overall survival at 2-years, to study the patterns of disease recurrence following this treatment, to study the pharmacology of intraperitoneal gemcitabine and to study changes in peritoneal cytology with pancreatic cancer resection.
Primary Outcome
Incidence of grade III and IV complications related to intraopertaive intraperitoneal gemcitabine occurring during hospitalization or within 30 days of surgery, whichever is longer
Interventions
- DRUG Intraperitoneal Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Why NCT01206296 stopped before completion
NCT01206296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Intraperitoneal Gemcitabine is the first listed.
NCT01206296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01206296 about?
NCT01206296 is a clinical study titled "Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma". This is a phase II study evaluating the use of intraperitoneal gemcitabine given intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer. The primary objective of this study is to evaluate the overall safety of intraperitoneal gemcitabine given intraoperatively and pos...
What is the current status of trial NCT01206296?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2010-08. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01206296?
The interventions under investigation include: Intraperitoneal Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01206296?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01206296's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia